索兰班和β-上腺素驱动之间的相互作用可能导致心肌病和早期死亡率
R Dash1, V Kadambi, A G Schmidt
1Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc, Cambridge, Massachusetts, USA.
Circulation
|February 15, 2001
概括
即使没有心力衰竭,同情心调的增加也可能导致心肌病. 这项研究表明,索兰班和上腺素驱动相互作用,导致小鼠心力衰竭和早期死亡.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 身体生理学 身体生理学
背景情况:
- 索兰班抑制了sarcoplasmic网膜的功能,这是beta-adrenergic刺激的关键目标.
- 慢性β-上腺素受体活性可能是有害的,但生理学同情基调的影响是未知的.
研究的目的:
- 为了调查生理学上的同情语调,如果没有先前存在的心力衰竭,是有害的.
- 为了阐明斯福兰班和增加上腺素驱动之间的相互作用.
主要方法:
- 产生的转基因小鼠过度表达索兰班.
- 评估心脏功能,心肌细胞机制和动力学.
- 用于评估体内心脏功能和交感声调的普拉诺洛尔.
主要成果:
- 转基因小鼠表现出抑郁的腹腔收缩性和心肌细胞功能,这种情况被异二醇逆转.
- 普罗普拉诺洛尔的使用抑制了心脏功能,表明了增强的交感声调.
- 转基因小鼠的衰老导致了腺环酸脱敏,心力衰竭和过早死亡.
结论:
- 补偿性增加catecholamine刺激可以导致心肌病和早期死亡,即使没有先前存在的心力衰竭.
- 突出了索兰班和上腺体驱动器在心脏病发展中的关键相互作用.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

